Almanack Investment Partners LLC. bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,909 shares of the company’s stock, valued at approximately $119,000.

Several other institutional investors have also made changes to their positions in the company. Guardian Life Insurance Co. of America increased its position in shares of Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after purchasing an additional 13 shares during the last quarter. Sii Investments Inc. WI grew its stake in shares of Zoetis by 0.3% during the 1st quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares during the period. Argent Trust Co grew its stake in shares of Zoetis by 0.8% during the 1st quarter. Argent Trust Co now owns 4,132 shares of the company’s stock worth $221,000 after acquiring an additional 32 shares during the period. Ironwood Investment Management LLC grew its stake in shares of Zoetis by 0.7% during the 2nd quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares during the period. Finally, Benjamin F. Edwards & Company Inc. grew its stake in shares of Zoetis by 1.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares during the period. 93.31% of the stock is owned by hedge funds and other institutional investors.

Shares of Zoetis Inc. (ZTS) traded up 0.28% during trading on Monday, hitting $64.88. The company had a trading volume of 229,027 shares. The stock has a market capitalization of $31.73 billion, a P/E ratio of 36.68 and a beta of 1.02. The firm’s 50 day moving average is $61.83 and its 200-day moving average is $59.05. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $65.39.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting analysts’ consensus estimates of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period in the prior year, the company earned $0.49 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. Equities research analysts anticipate that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. Cowen and Company set a $70.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price target on shares of Zoetis in a research note on Wednesday, September 6th. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 price target (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Tuesday, June 20th. Finally, Hilliard Lyons assumed coverage on Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $65.44.

ILLEGAL ACTIVITY WARNING: “Almanack Investment Partners LLC. Buys Shares of 1,909 Zoetis Inc. (ZTS)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/11/almanack-investment-partners-llc-buys-shares-of-1909-zoetis-inc-zts.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.